 Skye Bioscience inc OTCQB:SKYE said it has hired experienced Australian clinical trial operator CMAX to run its phase 1 study of lead candidate SBI-100 OE to treat glaucoma in Adelaide with final data expected in the fourth quarter this year. CMAX will conduct Skyes first-in-human single ascending dose SAD and multiple ascending dose MAD phase 1 study in healthy volunteers, evaluating safety and pharmacokinetics of SBI-100 OE under good clinical practice GCP. 